发明名称 |
COMBINATION THERAPY FOR NEOPLASIA TREATMENT |
摘要 |
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide. |
申请公布号 |
CA2903645(A1) |
申请公布日期 |
2014.09.12 |
申请号 |
CA20142903645 |
申请日期 |
2014.03.06 |
申请人 |
BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
发明人 |
ADAM, PAUL;FRIEDBICHLER, KATRIN |
分类号 |
A61K39/395;A61K31/00;C07K16/22;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|